Based on studies in people with chronic kidney disease (CKD), GLP-1 receptor agonists were shown to be safe (no increased risk for acute kidney injury (AKI) was observed) and efficacious also at lower eGFR ranges [25]. Here, GLP1R is linked to chronic kidney disease.